The scheduling of an FDA advisory committee meeting is a critical step in the drug approval process and can be seen as a positive development, as it moves the NDA closer to a potential approval. This news is likely to be viewed favorably by investors, which could lead to a short-term increase in Geron's stock price. However, the ultimate impact will depend on the outcome of the meeting and the committee's recommendations.